Journal of Atherosclerosis and Thrombosis,
Journal Year:
2023,
Volume and Issue:
31(5), P. 550 - 558
Published: Nov. 13, 2023
In
2022,
the
Japan
Atherosclerosis
Society
(JAS)
has
revised
its
clinical
diagnostic
criteria
of
familial
hypercholesterolemia
(FH)
and
adopted
use
definite,
probable,
possible,
unlikely
FH
according
to
Dutch
Lipid
Clinic
Network
(DLCN)
criteria.
However,
these
strata
have
not
been
validated
their
impact
on
coronary
artery
disease
(CAD)
is
yet
be
elucidated.
PLoS ONE,
Journal Year:
2025,
Volume and Issue:
20(1), P. e0317379 - e0317379
Published: Jan. 13, 2025
Introduction
Personalised
prevention
offers
a
promising
tool
to
reduce
the
impact
of
non-communicable
diseases,
which
represent
growing
health
burden
worldwide.
However,
support
adoption
this
innovation
it
is
needed
clarify
current
state
available
evidence
in
area.
This
work
aims
provide
an
overview
recent
publications
on
personalised
for
chronic
conditions.
Materials
and
methods
A
scoping
review
scientific
literature
from
Medline,
Scopus,
Web
Science
grey
was
conducted.
Eligible
articles
included
prospective
primary
studies
clinical
practice
directives
preventive
approaches
diseases
published
between
January
2017
December
2023.
The
followed
Arksey-O’Malley
guidelines
PRISMA-ScR
checklist.
Results
We
identified
121
including
60
cohort
61
directives.
extracted
249
approaches,
27%
prevention,
secondary
46%
tertiary
prevention.
In
50%
67
were
studies,
mainly
targeting
cardiovascular
primarily
focused
cancer.
Secondary
66
73%
concerning
breast
Tertiary
116
evenly
distributed
among
two
publication
types
focusing
mostly
cancer
diseases.
Lastly,
most
represented
level
both
research
(54%
41%
respectively).
Conclusions
Our
study
highlights
significant
focus
oncology
past
few
years,
with
numerous
recently
issued
substantial
original
indicating
interest
field.
distribution
across
three
levels
anticipate
challenges
generating
utility
falling
under
Journal of Atherosclerosis and Thrombosis,
Journal Year:
2023,
Volume and Issue:
30(11), P. 1525 - 1546
Published: Sept. 13, 2023
One
fifth
of
the
world
population
live
in
East
Asia
comprising
Japan,
Korea,
and
China
where
ischemic
heart
disease,
a
major
component
atherosclerotic
cardiovascular
disease
(ASCVD),
is
second
most
frequent
cause
death.
Each
low-density
lipoproteins
(LDL),
remnant
lipoproteins,
lipoprotein(a),
summarized
as
non-high-density
(non-HDL)
or
apolipoprotein
B
(apoB)
containing
causes
ASCVD.
However,
significant
proportion
evidence
on
lipoprotein
cholesterol
with
risk
ASCVD
came
from
White
people
mainly
living
Europe
North
America
not
Asian
descent.
With
unique
biological,
geohistorical,
social
background
this
region,
Asians
have
distinctive
characteristics
that
might
potential
impact
association
Considering
movement
across
national
borders
World,
understanding
important
for
both
non-East
populations
wherever
they
World.
JACC Case Reports,
Journal Year:
2024,
Volume and Issue:
29(12), P. 102367 - 102367
Published: May 12, 2024
We
present
a
young
boy
with
diagnosis
of
homozygous
familial
hypercholesterolemia
who
presented
statin
and
ezetimibe
resistance.
The
patient
received
lipoprotein
apheresis
at
6
years
age.
His
low-density
cholesterol
levels
significantly
were
reduced
by
adding
lomitapide
evinacumab,
his
carotid
plaque
started
to
regress.
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(17), P. 2927 - 2927
Published: Sept. 1, 2024
Dyslipidemia
is
a
significant
risk
factor
for
atherosclerotic
cardiovascular
disease
(ASCVD).
During
pregnancy,
physiological
changes
elevate
cholesterol
and
triglyceride
levels
to
support
fetal
development,
which
can
exacerbate
pre-existing
conditions
lead
complications
such
as
pre-eclampsia,
gestational
diabetes,
increased
ASCVD
both
mother
child.
Effective
management
strategies
are
necessary,
especially
pregnant
women
with
inherited
forms
of
dyslipidemia
(i.e.,
familial
hypertriglyceridemia,
hyperchylomicronemia),
where
personalized
dietary
adjustments
crucial
successful
pregnancy
outcomes.
Pharmacological
interventions
lipoprotein
apheresis
may
be
necessary
severe
cases,
though
their
use
often
limited
by
factors
cost,
availability,
potential
risks.
Despite
the
promise
advanced
therapies,
widespread
application
remains
constrained
studies
high
costs.
Thus,
personalized,
multidisciplinary
approach
essential
optimizing
This
review
provides
comprehensive
overview
current
evidence-based
practices
managing
during
emphasizing
balance
maternal
health.
Additionally,
it
discusses
in
lipid
metabolism
implications,
particularly
dyslipidemia.
Health Science Reports,
Journal Year:
2025,
Volume and Issue:
8(3)
Published: March 1, 2025
ABSTRACT
Background
and
Aims
Familial
hypercholesterolemia
(FH)
is
a
substantial
contributor
to
the
development
of
atherosclerotic
cardiovascular
disease.
Therefore,
primary
focus
our
study
was
examine
sex‐based
disparities
in
clinical
signs,
status,
lipid
profiles,
treatment
intensity
among
patients
with
FH
from
Vietnam.
Methods
This
retrospective
cross‐sectional
report
analyzed
profiles
110
Vietnam
Hypercholesterolemia
(VINAFH)
registry.
Results
Among
these
patients,
47
(42.7%)
were
females,
48
(43.6%)
had
mutant
FH.
Women
diagnosed
at
significantly
later
age
than
men.
However,
smoking
signs
suggestive
observed
more
frequently
males
females.
Male
exhibited
higher
prevalence
premature
coronary
artery
disease
No
significant
differences
plasma
total
cholesterol
low‐density
lipoprotein
(LDL‐C)
levels
between
sexes.
In
males,
areas
under
curve
(AUC)
for
LDL‐C
0.83,
cut‐off
value
6.11
mmol/L
(sensitivity,
79.4%;
specificity,
89.7%).
AUC
0.72,
6.9
57.1%;
93.9%).
Statins
prescribed
most
(93.6%),
proportion
men
women
receiving
high‐intensity
statin
therapy.
Conclusion
Our
findings
suggested
that
Vietnam,
women,
whereas
are
likely
smoke
have
Treatment
female
lower
male
despite
prescription.
Rare Disease and Orphan Drugs Journal,
Journal Year:
2025,
Volume and Issue:
4(2)
Published: April 24, 2025
Familial
hypercholesterolemia
(FH)
is
an
autosomal
dominant
inherited
disorder
characterized
by
elevated
low-density
lipoprotein
cholesterol
(LDL-C)
levels
and
skin
and/or
tendon
xanthomas.
FH
caused
mutations
in
genes
associated
with
the
LDL
receptor
pathway.
Heterozygous
frequently
encountered,
occurring
about
one
300
people,
30
people
coronary
artery
disease,
15
premature
disease
or
severe
hyperlipidemia.
Because
patients
are
exposed
to
high
LDL-C
concentrations
from
birth,
this
leads
progressive
atherosclerosis,
development
of
cardiovascular
events
these
15-20
years
younger
than
typical
age
onset.
Achilles
thickening
most
specific
physical
finding
FH,
although
it
also
observed
metabolic
diseases
such
as
sitosterolemia
cerebral
xanthomatosis
cases
rupture.
In
Japan,
criteria
include
a
diagnostic
criterion
addition
presence
Furthermore,
thicker
tendons
higher
risk
events.
Therefore,
measurement
thickness
beneficial
not
only
for
diagnosis
but
event
assessment.
It
hoped
that
will
improve
performance
lead
earlier
reduced
incidence
disease.
This
review
summarizes
usefulness
measuring
assessment
FH.
